CLYM

SEC source: 0001415889-25-015766 · form4-06052025_080655.xml · derivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director

RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2035-06-03

F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 4, 2026 or the day immediately prior to the next annual meeting of stockholders, subject to Dr. Andrew Levin's continuous service through such date.

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"),and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

F3 · ownership.nature: Dr. Andrew Levin is a Partner and Managing Director of the Adviser who serves on the Issuer's board of directors. Under Dr. Levin's arrangement with the Adviser, Dr. Levin holds the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account. Dr. Levin is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.

SEC source: 0000950170-25-082335 · ownership.xml · derivative · entry 1

Drapkin Kimberlee C · CIK 0001340881 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2035-06-03

F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 4, 2026 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date.

SEC source: 0000950170-25-082321 · ownership.xml · derivative · entry 1

Levin Andrew David · CIK 0001867539 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2035-06-03

F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 4, 2026 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date.

F2 · ownership.direct: Under the reporting person's arrangement with RA Capital Management, L.P. (the "Adviser"), the reporting person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The reporting person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account to the Adviser. The reporting person therefore disclaims beneficial ownership of the stock option and underlying common stock.

SEC source: 0000950170-25-048558 · ownership.xml · derivative · entry 1

WILLIAMS DOUGLAS E · CIK 0001184847 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,873

Underlying: Common Stock · 78,873 shares

Expires 2035-03-30

F1 · derivative.exercise_date: The shares underlying the option vest in equal monthly installments from November 8, 2024 (the "Vesting Commencement Date") until the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service.

SEC source: 0000950170-25-048549 · ownership.xml · derivative · entry 1

Cumbo Alexander · CIK 0001685994 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2035-03-27

F1 · derivative.exercise_date: The shares underlying the option vest in equal monthly installments from March 28, 2025 (the "Vesting Commencement Date") until the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service.

SEC source: 0000950170-25-048555 · ownership.xml · derivative · entry 1

Drapkin Kimberlee C · CIK 0001340881 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2035-03-27

F1 · derivative.exercise_date: The shares underlying the option vest in equal monthly installments from March 28, 2025 (the "Vesting Commencement Date") until the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service.

SEC source: 0000950170-25-046083 · ownership.xml · derivative · entry 2

Thomas Stephen Basil · CIK 0002027962 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,094

Underlying: Common Stock · 25,093 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F3 · derivative.exercise_date: The RSUs were granted on June 27, 2024 and vested as to 50% of the shares on January 1, 2025, vested as to 25% of the shares on March 27, 2025 and will vest as to the remaining 25% of the shares on June 27, 2025, subject to the Reporting Person's continued service.

F3 · derivative.expiration_date: The RSUs were granted on June 27, 2024 and vested as to 50% of the shares on January 1, 2025, vested as to 25% of the shares on March 27, 2025 and will vest as to the remaining 25% of the shares on June 27, 2025, subject to the Reporting Person's continued service.

SEC source: 0000950170-25-046083 · ownership.xml · nonDerivative · entry 1

Thomas Stephen Basil · CIK 0002027962 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 179,188

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") converted into one share of the Issuer's Common Stock.

SEC source: 0000950170-25-042777 · ownership.xml · nonDerivative · entry 2

Pimblett Emily · CIK 0001969365 · SVP, Finance & CAO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,130

F2 · kind: The sale reported on this Form 4 was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on April 27, 2024 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices within the range of $1.31 to $1.325, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

SEC source: 0000950170-25-042777 · ownership.xml · derivative · entry 3

Pimblett Emily · CIK 0001969365 · SVP, Finance & CAO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 5,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F5 · derivative.exercise_date: The shares subject to this RSU shall vest at a rate of 1/8th of the total number of shares on the three-month anniversary of March 18, 2024 (the "March 2024 Vesting Commencement Date") and 1/8th of the total number of shares each three-month anniversary of the March 2024 Vesting Commencement Date thereafter for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the two-year anniversary of the March 2024 Vesting Commencement Date.

F5 · derivative.expiration_date: The shares subject to this RSU shall vest at a rate of 1/8th of the total number of shares on the three-month anniversary of March 18, 2024 (the "March 2024 Vesting Commencement Date") and 1/8th of the total number of shares each three-month anniversary of the March 2024 Vesting Commencement Date thereafter for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the two-year anniversary of the March 2024 Vesting Commencement Date.

SEC source: 0000950170-25-042777 · ownership.xml · nonDerivative · entry 1

Pimblett Emily · CIK 0001969365 · SVP, Finance & CAO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,329

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") converted into one share of the Issuer's Common Stock.

SEC source: 0000950170-25-005840 · ownership.xml · derivative · entry 1

Brennan Aoife · CIK 0001714563 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,150,000

Underlying: Common Stock · 1,150,000 shares

Expires 2035-01-12

F1 · derivative.exercise_date: This option was granted on January 13, 2025 (the "Grant Date"). The shares underlying the option are scheduled to vest with respect to 25% of the shares on the first anniversary of the Grant Date and the remainder are scheduled to vest in 36 equal monthly installments through January 13, 2029, subject to the Reporting Person's continued service.

SEC source: 0000950170-25-005836 · ownership.xml · derivative · entry 1

Kaplan Brett · CIK 0001778763 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Common Stock · 500,000 shares

Expires 2035-01-12

F1 · derivative.exercise_date: This option was granted on January 13, 2025 (the "Grant Date"). The shares underlying the option are scheduled to vest with respect to 25% of the shares on the first anniversary of the Grant Date and the remainder are scheduled to vest in 36 equal monthly installments through January 13, 2029, subject to the Reporting Person's continued service.

SEC source: 0000950170-25-005839 · ownership.xml · derivative · entry 1

Pimblett Emily · CIK 0001969365 · SVP, Finance and CAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2035-01-12

F1 · derivative.exercise_date: This option was granted on January 13, 2025 (the "Grant Date"). The shares underlying the option are scheduled to vest with respect to 25% of the shares on the first anniversary of the Grant Date and the remainder are scheduled to vest in 36 equal monthly installments through January 13, 2029, subject to the Reporting Person's continued service.

SEC source: 0000950170-25-001176 · ownership.xml · derivative · entry 2

Thomas Stephen Basil · CIK 0002027962 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,187

Underlying: Common Stock · 50,188 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F3 · derivative.exercise_date: The RSUs were granted on June 27, 2024 and will vest as to 50% of the shares on January 1, 2025, as to 25% of the shares on March 27, 2025 and as to the remaining 25% of the shares on June 27, 2025, subject to the Reporting Person's continued service.

F3 · derivative.expiration_date: The RSUs were granted on June 27, 2024 and will vest as to 50% of the shares on January 1, 2025, as to 25% of the shares on March 27, 2025 and as to the remaining 25% of the shares on June 27, 2025, subject to the Reporting Person's continued service.

SEC source: 0000950170-25-001176 · ownership.xml · nonDerivative · entry 1

Thomas Stephen Basil · CIK 0002027962 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 154,095

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") converted into one share of the Issuer's Common Stock.

SEC source: 0000950170-24-139052 · ownership.xml · nonDerivative · entry 2

Pimblett Emily · CIK 0001969365 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 11,329

F2 · kind: The sale reported on this Form 4 was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on April 27, 2024 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs.

SEC source: 0000950170-24-139052 · ownership.xml · derivative · entry 3

Pimblett Emily · CIK 0001969365 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 5,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F4 · derivative.exercise_date: The shares subject to this RSU shall vest at a rate of 1/8th of the total number of shares on the three-month anniversary of March 18, 2024 (the "March 2024 Vesting Commencement Date") and 1/8th of the total number of shares each three-month anniversary of the March 2024 Vesting Commencement Date thereafter for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the two-year anniversary of the March 2024 Vesting Commencement Date.

F4 · derivative.expiration_date: The shares subject to this RSU shall vest at a rate of 1/8th of the total number of shares on the three-month anniversary of March 18, 2024 (the "March 2024 Vesting Commencement Date") and 1/8th of the total number of shares each three-month anniversary of the March 2024 Vesting Commencement Date thereafter for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the two-year anniversary of the March 2024 Vesting Commencement Date.

SEC source: 0000950170-24-139052 · ownership.xml · nonDerivative · entry 1

Pimblett Emily · CIK 0001969365 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,564

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") converted into one share of the Issuer's Common Stock.

SEC source: 0000950170-24-125717 · ownership.xml · derivative · entry 2

WILLIAMS DOUGLAS E · CIK 0001184847 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,291

Underlying: Common Stock · 6,291 shares

Expires 2034-11-10

F2 · derivative.exercise_date: The shares underlying the option vest on the earlier of June 26, 2025 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continued service.

SEC source: 0000950170-24-125717 · ownership.xml · derivative · entry 1

WILLIAMS DOUGLAS E · CIK 0001184847 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2034-11-10

F1 · derivative.exercise_date: The shares underlying the option vest in equal monthly installments from November 8, 2024 (the "Vesting Commencement Date") until the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service.

SEC source: 0000950170-24-108582 · ownership.xml · nonDerivative · entry 3

Pimblett Emily · CIK 0001969365 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,564

F2 · kind: The sale reported on this Form 4 was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on April 27, 2024 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs.

SEC source: 0000950170-24-108582 · ownership.xml · nonDerivative · entry 2

Pimblett Emily · CIK 0001969365 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,573

F2 · kind: The sale reported on this Form 4 was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on April 27, 2024 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs.

SEC source: 0000950170-24-108582 · ownership.xml · derivative · entry 4

Pimblett Emily · CIK 0001969365 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 5,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F4 · derivative.exercise_date: The shares subject to this RSU shall vest at a rate of 1/8th of the total number of shares on the three-month anniversary of March 18, 2024 (the "March 2024 Vesting Commencement Date") and 1/8th of the total number of shares each three-month anniversary of the March 2024 Vesting Commencement Date thereafter for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the two-year anniversary of the March 2024 Vesting Commencement Date.

F4 · derivative.expiration_date: The shares subject to this RSU shall vest at a rate of 1/8th of the total number of shares on the three-month anniversary of March 18, 2024 (the "March 2024 Vesting Commencement Date") and 1/8th of the total number of shares each three-month anniversary of the March 2024 Vesting Commencement Date thereafter for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the two-year anniversary of the March 2024 Vesting Commencement Date.

SEC source: 0000950170-24-108582 · ownership.xml · nonDerivative · entry 1

Pimblett Emily · CIK 0001969365 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,755

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") converted into one share of the Issuer's Common Stock.

SEC source: 0000950170-24-100633 · ownership.xml · derivative · entry 2

Kaplan Brett · CIK 0001778763 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,500

Underlying: Common Stock · 77,500 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon vesting.

F3 · derivative.exercise_date: The RSUs were granted on the Grant Date and are scheduled to vest over four years, with 25% of the shares vesting on each of the first four anniversaries of the Grant Date, subject to the Reporting Person's continued service.

F3 · derivative.expiration_date: The RSUs were granted on the Grant Date and are scheduled to vest over four years, with 25% of the shares vesting on each of the first four anniversaries of the Grant Date, subject to the Reporting Person's continued service.

SEC source: 0000950170-24-100633 · ownership.xml · derivative · entry 1

Kaplan Brett · CIK 0001778763 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 465,000

Underlying: Common Stock · 465,000 shares

Expires 2034-08-25

F1 · derivative.exercise_date: This option was granted on August 26, 2024 (the "Grant Date"). The shares underlying the option are scheduled to vest with respect to 25% of the shares on the first anniversary of the Grant Date and the remainder are scheduled to vest in 36 equal monthly installments through August 26, 2028, subject to the Reporting Person's continued service.

SEC source: 0001415889-24-019946 · form4-07232024_090751.xml · nonDerivative · entry 4

Morisset Valerie · CIK 0001868517 · EVP, R&D AND CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,317

SEC source: 0001415889-24-019946 · form4-07232024_090751.xml · nonDerivative · entry 3

Morisset Valerie · CIK 0001868517 · EVP, R&D AND CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,317

SEC source: 0001415889-24-019946 · form4-07232024_090751.xml · nonDerivative · entry 2

Morisset Valerie · CIK 0001868517 · EVP, R&D AND CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,322

SEC source: 0001415889-24-019946 · form4-07232024_090751.xml · nonDerivative · entry 1

Morisset Valerie · CIK 0001868517 · EVP, R&D AND CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,322

SEC source: 0001415889-24-019814 · form4-07192024_030734.xml · nonDerivative · entry 2

Morisset Valerie · CIK 0001868517 · EVP, R&D AND CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 160,523

SEC source: 0001415889-24-019814 · form4-07192024_030734.xml · nonDerivative · entry 1

Morisset Valerie · CIK 0001868517 · EVP, R&D AND CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 199,099

SEC source: 0001415889-24-019706 · form4-07172024_100719.xml · nonDerivative · entry 1

Morisset Valerie · CIK 0001868517 · EVP, R&D AND CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 202,306

SEC source: 0001415889-24-019610 · form4-07162024_100734.xml · nonDerivative · entry 2

Morisset Valerie · CIK 0001868517 · EVP, R&D AND CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 252,306

SEC source: 0001415889-24-019610 · form4-07162024_100734.xml · nonDerivative · entry 1

Morisset Valerie · CIK 0001868517 · EVP, R&D AND CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 294,683

SEC source: 0001415889-24-019504 · form4-07122024_120744.xml · nonDerivative · entry 3

Morisset Valerie · CIK 0001868517 · EVP, R&D AND CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 344,683

SEC source: 0001415889-24-019504 · form4-07122024_120744.xml · nonDerivative · entry 2

Morisset Valerie · CIK 0001868517 · EVP, R&D AND CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 394,683

SEC source: 0001415889-24-019504 · form4-07122024_120744.xml · nonDerivative · entry 1

Morisset Valerie · CIK 0001868517 · EVP, R&D AND CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 444,683

SEC source: 0001415889-24-019433 · form4-07092024_080757.xml · nonDerivative · entry 1

Morisset Valerie · CIK 0001868517 · EVP, R&D AND CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 450,614

SEC source: 0001415889-24-019147 · form4-07032024_060700.xml · nonDerivative · entry 2

Morisset Valerie · CIK 0001868517 · EVP, R&D AND CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 462,956

SEC source: 0001415889-24-019147 · form4-07032024_060700.xml · derivative · entry 3

Morisset Valerie · CIK 0001868517 · EVP, R&D AND CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,198

Underlying: Common Stock · 7,649 shares

Expires 2031-02-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The shares subject to this option shall vest at a rate of 12/48ths of the total number of shares on the one-year anniversary of February 26, 2021 (the "February 2021 Vesting Commencement Date") and 1/48thof the total number of shares each monthly anniversary of the February 2021 Vesting Commencement Date thereafter (or if there is no corresponding day, on the last day of the month) for so long as the Reporting Person remains an officer, director, employee, consultant and/or advisor of the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the February 2021Vesting Commencement Date.

SEC source: 0001415889-24-019147 · form4-07032024_060700.xml · nonDerivative · entry 1

Morisset Valerie · CIK 0001868517 · EVP, R&D AND CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 512,956

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-24-078685 · ownership.xml · derivative · entry 2

Thomas Stephen Basil · CIK 0002027962 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,375

Underlying: Common Stock · 100,375 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon vesting.

F3 · derivative.exercise_date: The RSUs were granted on June 27, 2024 and will vest as to 50% of the shares on January 1, 2025, as to 25% of the shares on March 27, 2025 and as to the remaining 25% of the shares on June 27, 2025, subject to the Reporting Person's continued service.

F3 · derivative.expiration_date: The RSUs were granted on June 27, 2024 and will vest as to 50% of the shares on January 1, 2025, as to 25% of the shares on March 27, 2025 and as to the remaining 25% of the shares on June 27, 2025, subject to the Reporting Person's continued service.

SEC source: 0000950170-24-078685 · ownership.xml · nonDerivative · entry 1

Thomas Stephen Basil · CIK 0002027962 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 103,907

F1 · price: The Reporting Person acquired 103,907 shares of the issuer's common stock in exchange for 838,000 shares of common stock of Tenet Medicines, Inc. ("Tenet") in connection with the issuer's acquisition of all of the outstanding common stock of Tenet on June 27, 2024 (the "Acquisition"). On the effective date of the Acquisition, the closing price of the issuer's common stock was $7.53 per share.

SEC source: 0000950170-24-078688 · ownership.xml · derivative · entry 2

Brennan Aoife · CIK 0001714563 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 275,000

Underlying: Common Stock · 275,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon vesting.

F3 · derivative.exercise_date: The RSUs were granted on the Grant Date and are scheduled to vest over four years, with 25% of the shares vesting on each of the first four anniversaries of the Grant Date, subject to the Reporting Person's continued service.

F3 · derivative.expiration_date: The RSUs were granted on the Grant Date and are scheduled to vest over four years, with 25% of the shares vesting on each of the first four anniversaries of the Grant Date, subject to the Reporting Person's continued service.

SEC source: 0000950170-24-078688 · ownership.xml · derivative · entry 1

Brennan Aoife · CIK 0001714563 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 550,000

Underlying: Common Stock · 550,000 shares

Expires 2034-06-26

F1 · derivative.exercise_date: This option was granted on June 27, 2024 (the "Grant Date"). The shares underlying the option are scheduled to vest with respect to 25% of the shares on the first anniversary of the Grant Date and the remainder are scheduled to vest in 36 equal monthly installments through June 27, 2028, subject to the Reporting Person's continued service.

SEC source: 0001415889-24-018708 · form4-07022024_010700.xml · nonDerivative · entry 5

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director

RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 2,866,375

F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus II Fund, L.P. (the "Nexus Fund II"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Fund and the Nexus Fund III collectively own approximately 81% of the outstanding equity interests of Sera Medicines, LLC ("Sera"). Accordingly, each of the Fund, the Nexus Fund III and the Adviser may be deemed to beneficially own the securities held by Sera. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein.

F5 · ownership.nature: These securities are held directly by Nexus Fund III.

SEC source: 0001415889-24-018708 · form4-07022024_010700.xml · nonDerivative · entry 4

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director

RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 23,521,757

F2 · ownership.nature: These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund").

F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus II Fund, L.P. (the "Nexus Fund II"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Fund and the Nexus Fund III collectively own approximately 81% of the outstanding equity interests of Sera Medicines, LLC ("Sera"). Accordingly, each of the Fund, the Nexus Fund III and the Adviser may be deemed to beneficially own the securities held by Sera. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein.

SEC source: 0001415889-24-018708 · form4-07022024_010700.xml · nonDerivative · entry 3

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director

RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 1,807,000

F1 · price: Received in exchange for equity of Tenet Medicines, Inc. ("Tenet") pursuant to an Agreement and Plan of Merger and Reorganization, dated April 10, 2024, by and among the Issuer, Tango Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Tango Merger Sub") and Tenet (the "Acquisition Agreement"). Under the terms of the Acquisition Agreement, on June 27, 2024, Tenet was acquired by the Issuer through the merged of Tango Merger Sub with and into Tenet (the "Acquisition"), with Tenet surviving the Acquisition as a wholly-owned subsidiary of the Issuer.

F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus II Fund, L.P. (the "Nexus Fund II"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Fund and the Nexus Fund III collectively own approximately 81% of the outstanding equity interests of Sera Medicines, LLC ("Sera"). Accordingly, each of the Fund, the Nexus Fund III and the Adviser may be deemed to beneficially own the securities held by Sera. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein.

F5 · ownership.nature: These securities are held directly by Nexus Fund III.